Saltar al contenido
Merck

Identification of Glypican-3 as a potential metastasis suppressor gene in gastric cancer.

Oncotarget (2016-06-04)
Shiwei Han, Xuemei Ma, Yanxia Zhao, Hongying Zhao, Ana Batista, Sheng Zhou, Xiaona Zhou, Yao Yang, Tingting Wang, Jingtao Bi, Zheng Xia, Zhigang Bai, Igor Garkavtsev, Zhongtao Zhang
RESUMEN

Gastric cancer is a prevalent tumor that is usually detected at an advanced metastatic stage. Currently, standard therapies are mostly ineffective. Here, we report that Glypican-3 (GPC3) is absent in invasive tumors and metastatic lymph nodes, in particular in aggressive and highly disseminated signet ring cell carcinomas. We demonstrate that loss of GPC3 correlates with poor overall survival in patients. Moreover, we show that absence of GPC3 causes up-regulation of MAPK/FoxM1 signaling and that blockade of this pathway alters cellular invasion. An inverse correlation between GPC3 and FoxM1 is also shown in patient samples. These data identify GPC3 as a potential metastasis suppressor gene and suggest its value as a prognostic marker in gastric cancer. Development of therapies targeting signaling downstream of GPC3 are warranted.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-GPC3 Antibody, clone 9C2, ascites fluid, clone 9C2, from mouse